As of 2025-10-15, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.9x - 11.0x | 7.8x |
| Forward P/E multiples | 9.0x - 16.0x | 12.6x |
| Fair Price | (112.03) - (138.77) | (127.74) |
| Upside | -2205.9% - -2708.5% | -2501.2% |
| Date | EV/EBITDA |